Drugging the Medullary Thyroid Cancer Surfaceome with T Cell Engagers Targeting CEA, GFRA4 and DLL3 as Monotherapy and In Combination with Tyrosine Kinase Inhibitors

This study identifies CEA, DLL3, and GFRA4 as promising targets for T cell engagers in medullary thyroid cancer, demonstrating that the resulting bispecific antibodies effectively induce T cell-mediated cytotoxicity and show enhanced efficacy when combined with tyrosine kinase inhibitors in preclinical models.

The Gist

The Big Picture: A New Weapon Against a Tough Foe

Imagine Medullary Thyroid Cancer (MTC) as a very stubborn, shape-shifting criminal hiding in a city (the body). Currently, if surgery can't catch them, doctors have very few tools left. The existing weapons (chemotherapy and radiation) often miss the mark, and the "police" (the body's immune system) usually ignore the criminal because the criminal wears a disguise.

This paper introduces a new, high-tech police unit called T Cell Engagers (TCEs). Think of these as biological "Wanted" posters that act as a bridge. One end of the poster sticks to the criminal (the cancer cell), and the other end grabs a police officer (a T cell) and physically drags them right up to the criminal to make an arrest (kill the cell).

The author, Tim Erickson, is proposing a strategy to use these "Wanted posters" specifically for MTC, targeting three specific "identifying marks" on the cancer cells: CEA, DLL3, and GFRA4.

---

Step 1: Finding the Criminal's Identifying Marks (The Targets)

To catch a criminal, you need to know what they look like. The researcher analyzed 30 tumors from MTC patients to find unique "badges" on the surface of the cancer cells that healthy cells don't wear (or wear very little).

• The Search: They looked at the "surfaceome" (the outer skin of the cell) and filtered out anything that was too common (like a generic t-shirt) or found in too many healthy places (like a face on every street corner).
• The Winners: They found three specific badges:
  1. CEA: A common marker, but in MTC, it's stuck on the "back door" of the cell, making it a safe target.
  2. DLL3: A badge often found on aggressive cancers. It's like a "danger" sign.
  3. GFRA4: A badge almost exclusively found on thyroid cells. It's like a unique tattoo that only the criminal has.

The Analogy: Imagine the criminal wears a red hat (CEA), a blue scarf (DLL3), and has a specific scar on their cheek (GFRA4). The goal is to make a "Wanted" poster that recognizes these specific items.

Step 2: Building the "Wanted Posters" (The MTCEs)

The researcher built three different versions of these T Cell Engagers (called MTCEs):

1. One that grabs the Red Hat (Anti-CEA).
2. One that grabs the Blue Scarf (Anti-DLL3). Note: This one is actually an existing drug called Tarlatamab, already approved for lung cancer, so it's ready to go!
3. One that grabs the Scar (Anti-GFRA4).

How they work:

• The Left Hand: Grabs the cancer cell by its specific badge.
• The Right Hand: Grabs a T cell (the immune system's soldier) by its CD3 handle.
• The Result: The T cell is forced to stand right next to the cancer cell, forming a "kill zone" where the T cell destroys the cancer.

Step 3: Testing the Weapons in the Lab

The researcher tested these weapons in a petri dish (in vitro) using cancer cells and T cells.

• The Test: They mixed the cancer cells, the T cells, and the "Wanted posters."
• The Result: The T cells went into action immediately.
  • When the cancer cells had the badges, they were destroyed efficiently (even at very low doses of the drug).
  • When the cancer cells didn't have the badges (or were healthy cells), the T cells ignored them. This is crucial—it means the drug is precise and won't accidentally attack healthy tissue.
  • Live Video: They took photos showing the cancer cells clumping together and dying when the "Wanted posters" were present.

Step 4: The "Double-Team" Strategy (Combination Therapy)

Criminals are tricky; sometimes they change their appearance to escape. If a cancer cell loses its "Red Hat" (CEA), a drug looking only for the Red Hat will miss it.

• The Problem: Some MTC cells might stop showing one badge but keep the others.
• The Solution: The researcher tested using all three posters at once.
  • Analogy: Instead of just looking for the Red Hat, the police now look for the Hat, the Scarf, and the Scar. Even if the criminal takes off the hat, they still have the scarf and the scar.
  • The Result: Using all three together was much more effective at killing the cancer cells, especially those that tried to hide by dropping one badge.

Step 5: Teamwork with Existing Drugs (TKIs)

Doctors already have drugs called Tyrosine Kinase Inhibitors (TKIs) (like Selpercatinib) that slow down cancer growth. The researcher asked: Can we use the new "Wanted posters" alongside these old drugs?

• The Test: They treated the cancer cells with the old drugs first, then added the new "Wanted posters."
• The Result: It worked great! The old drugs didn't stop the new ones. In fact, the old drugs seemed to shrink the cancer slightly, which might actually make it easier for the T cells to finish the job. It's like the old drugs weaken the criminal's armor, making it easier for the T cells to break through.

Why This Matters

1. No Cure Yet: Currently, if MTC spreads (metastasizes), there is no cure. This offers a potential path to a cure.
2. Precision: These drugs are like smart missiles, not a carpet bomb. They only kill cells with the specific badges.
3. Overcoming Evasion: By targeting three different badges at once, it's much harder for the cancer to "hide" or escape.
4. Immediate Potential: Since the DLL3 drug is already approved for lung cancer, it could potentially be used for MTC patients right away (off-label), while the other two are in development.

The Bottom Line

This paper is a "proof of concept." It says, "We found three unique spots on MTC cancer cells. We built a tool that grabs those spots and drags the immune system to kill the cancer. It works in the lab, it works even better when we use all three tools together, and it plays nicely with existing drugs."

While this is just the lab stage (like testing a new car engine on a track), the results are promising enough to suggest that this could one day revolutionize how we treat this difficult disease, potentially turning a fatal diagnosis into a curable one.

Technical Summary

1. Problem Statement

Medullary Thyroid Cancer (MTC) is a rare neuroendocrine tumor originating from parafollicular C-cells. While localized MTC can be cured surgically, metastatic MTC currently lacks a curative therapy.

• Limitations of Current Treatments: MTC does not concentrate radioactive iodine (unlike differentiated thyroid cancer) and is generally resistant to cytotoxic chemotherapy.
• Tyrosine Kinase Inhibitors (TKIs): Drugs like selpercatinib and cabozantinib offer survival benefits for RET-mutant patients but have limited efficacy in RET wild-type patients and are associated with cumulative toxicities.
• Immunotherapy Gap: MTC has historically proven resistant to immune checkpoint inhibitors and tumor-antigen vaccines. There is an urgent medical need for novel therapeutic strategies capable of eradicating metastatic disease.

2. Methodology

The study employed a multi-step translational approach to identify targets, engineer biologics, and validate efficacy in vitro.

• Target Identification:
  • Analyzed bulk RNA sequencing data from 30 MTC patient tumors (26 primary, 4 lymph node metastases).
  • Cross-referenced with the TRON cell line database and the Human Protein Atlas.
  • Filtered for the "surfaceome" (3,412 extracellular proteins) and ranked genes based on high median expression in MTC, high differential expression (MTC vs. non-MTC cell lines), and restricted normal tissue expression to minimize on-target/off-tumor toxicity.
  • Selected Targets: CEA (CEACAM5), DLL3, and GFRA4.
• Antigen Validation:
  • Validated surface expression of CEA, DLL3, and GFRA4 on MTC cell lines (TT and MZ-CRC-1) and a Small Cell Lung Cancer (SCLC) line (SHP-77) using flow cytometry.
• Biologic Engineering (MTCEs):
  • Developed MTC-targeted T Cell Engagers (MTCEs).
  • Anti-CEA and Anti-GFRA4: Generated via murine immunization, AI-based affinity maturation, and humanization. Constructed as single-chain variable fragments (scFv) linked to a proprietary anti-CD3 scFv and an Fc-silenced half-life extension domain.
  • Anti-DLL3: Utilized the FDA-approved TCE tarlatamab as a proof-of-concept agent.
• Functional Assays:
  • Binding Assays: Flow cytometry to quantify binding affinity to CD4/CD8 T cells and target antigens on transduced CHO cells.
  • Cytotoxicity Assays: XTT assays and live-cell imaging to measure T cell-dependent lysis of MTC cells.
  • Combination Studies: Tested MTCEs alone and in combination with TKIs (selpercatinib and cabozantinib) and in multi-antigen combinations to assess resistance mechanisms.
  • Donor Variability: Validated mechanisms of action using T cells from five independent healthy donors.

3. Key Contributions

• First Application of TCEs in MTC: This study represents the first preclinical evaluation of T cell engagers specifically for Medullary Thyroid Cancer.
• Target Discovery Pipeline: Established a rigorous bioinformatic pipeline to identify CEA, DLL3, and GFRA4 as viable targets with favorable safety profiles (restricted normal tissue expression).
• Novel Biologics: Successfully engineered and characterized novel humanized anti-CEA and anti-GFRA4 MTCEs.
• Combination Strategy: Demonstrated functional compatibility between MTCEs and standard-of-care TKIs, suggesting a synergistic approach to overcome resistance and reduce toxicity.
• Antigen Escape Mitigation: Proposed and validated a "triple-target" strategy to prevent tumor escape via antigen loss.

4. Key Results

• Target Expression:
  • TT Cells: Highly expressed all three antigens (CEA, DLL3, GFRA4).
  • MZ Cells: Expressed DLL3 and moderate CEA, but showed negligible GFRA4 expression.
  • SHP-77: Expressed DLL3 and moderate CEA; no GFRA4.
• Binding and Specificity:
  • All MTCEs bound CD8+ and CD4+ T cells with high affinity (detectable at ~10 ng/mL).
  • Binding was strictly target-dependent; no cross-reactivity or off-target binding to antigen-negative cell lines was observed.
• Cytotoxicity (Monotherapy):
  • MTCEs mediated potent, concentration-dependent cytotoxicity against MTC cells in the presence of T cells.
  • Anti-DLL3 (Tarlatamab): Showed the broadest and most potent activity (EC50 ~0.2–2 ng/mL) against both TT and MZ lines.
  • Anti-CEA: Potent against TT cells; reduced efficacy against MZ cells (correlating with lower CEA expression).
  • Anti-GFRA4: Potent against TT cells but ineffective against MZ cells due to lack of target expression.
  • Specificity: No cytotoxicity was observed against antigen-negative controls (LNCaP, SKOV3, Raji, CHO-wt) or with the non-targeting control (gresonitamab).
• Combination with TKIs:
  • Co-treatment with selpercatinib or cabozantinib did not inhibit MTCE activity.
  • While TKIs slightly reduced IFNγ secretion (likely due to reduced tumor surface area), they numerically enhanced cytotoxicity, suggesting functional compatibility.
• Combination of MTCEs (Triple Therapy):
  • In MZ cells (GFRA4-negative), anti-GFRA4 monotherapy failed. However, a triple-combination (Anti-CEA + Anti-DLL3 + Anti-GFRA4) at reduced doses restored potent cytotoxicity, effectively overcoming single-antigen loss.
  • In heterogeneous tumor models (mix of CHO-CEA, CHO-DLL3, CHO-GFRA4), the triple-combination significantly outperformed any monotherapy (p < 0.001).
• Donor Variability:
  • The mechanism of action was consistent across T cells from five different healthy donors, confirming the findings are not donor-specific.

5. Significance and Future Outlook

• Paradigm Shift: This work proposes a new treatment paradigm for metastatic MTC, moving from TKI management to potential curative eradication using endogenous T cells.
• Addressing Heterogeneity: The study highlights that MTC tumors are heterogeneous (varying antigen expression). The data strongly supports a multi-antigen targeting strategy to prevent "antigen-loss escape," a common failure mode in immunotherapy.
• Clinical Potential:
  • Tarlatamab (anti-DLL3) is immediately available for off-label use in MTC patients with high DLL3 expression.
  • Combination Therapy: The synergy between MTCEs and TKIs offers a pathway to treat bulky disease while potentially reducing cytokine release syndrome (CRS) by shrinking tumor burden first.
  • Adjuvant Setting: MTCEs could serve as an adjuvant therapy to eradicate minimal residual disease, analogous to radioactive iodine in differentiated thyroid cancer.
• Next Steps: Future work requires comprehensive analysis of target expression in distant metastases (lungs, liver, bone), assessment of the tumor immune microenvironment, and clinical trials to validate these preclinical findings.

In conclusion, this paper provides a robust preclinical rationale for developing multi-antigen T cell engagers as a transformative therapy for metastatic Medullary Thyroid Cancer, offering a potential solution to a disease that currently has no cure.